2096 — Simcere Pharmaceutical Share News
0.000.00%
Last trade - 00:00- HK$27.27bn
- HK$24.00bn
- CNY7.73bn
Brief: Simcere Pharmaceutical Says SIM0500 For Injection Granted U.S. FDA Fast Track Designation
China's Simcere Pharma jumps on profit growth, share buyback hike
Brief: Simcere Pharmaceutical Says FY Profit Attributable RMB715 Mln
Brief: Simcere Pharmaceutical Revises Maximum Aggregate Price Under Existing Share Repurchase To RMB1 Bln
Brief: Simcere Pharmaceutical Says New Drug Application Of Suvemcitug Accepted By NMPA
Brief: Simcere Pharmaceutical Says Clinical Trial Approval For SIM0500 For Injection Issued By NMPA
Brief: Simcere Pharmaceutical Says Publication By New England Journal Of Medicine For COVID-19 Drug
Brief: Simcere Pharmaceutical Says Clinical Trial Approval For Sim0501 Tablets Issued By National Medical Products Administration
Brief: Simcere Pharmaceutical Says Phase-3 Clinical Study Of Suvemcitug Met Primary Study Endpoint
Brief: Simcere Pharmaceutical Says Jiangsu Simcere To Provide Certain Order Collection Comprehensive Services
Brief: Simcere Pharmaceutical Says Localization Application Of Cosela Approved By NMPA Of China
Brief: Simcere Pharmaceutical Says Approval Of Investigational New Drug For Sim0501 By U.S. FDA
Brief: Simcere Pharmaceutical Says Clinical Trial Approval For New Indication Of Sanbexin Sublingual Tablets
Brief: Simcere Pharmaceutical Says Entered Exclusive License And Collaboration Agreement
Brief: Simcere Pharmaceutical Announces Regular Approval Of Cosela®
Brief: Simcere Pharmaceutical Says Clinical Trial Approval For New Indication Of Sim0237 For Injection Issued By NMPA
Brief: Simcere Pharmaceutical Posts HY Profit Attributable RMB2,275 Mln
Brief: Simcere Pharmaceutical Says Marketing Application Of New Indication Of Cosela Accepted By NMPA
Brief: Simcere Pharmaceutical Says SIM0278 Injection (Il-2 Mutant FC Fusion Protein) Obtained Clinical Trial Approval